The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
An article from
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
Published June 30, 2026
Bristol Myers Squibb is one of the backers in Beeline's Series A extension, which the startup says will be used to advance several of the drugs it licensed from the pharma.
Alamy
Autoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures
BridgeBio attracts $1B in equity for new launches, but analyst smells M&A ‘dry powder’
BridgeBio adds $1B as it prepares three more drug launches
BeOne’s Brukinsa hits goal in mantle cell lymphoma confirmatory trial
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common…
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese…
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19,…
